ArticleScientific reports2025
Exploring the cytotoxic effects of bioactive compounds from Alcea rosea against stem cell driven colon carcinogenesis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Restoring apoptosis in breast cancer via peptide mediated disruption of survivin IAP interaction.Scientific reports · 2025Article
- Honeybee associated Aspergillus niger AW17 as a source of selective anticancer compounds with cytotoxicity evaluation in human cancer cell lines.Scientific reports · 2025Article
- AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression.Cell death discovery · 2025Article
- Anti-inflammatory and anticancer properties ofFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Seven compounds were isolated from ethyl acetate extract of Alcea rosea and were examined for their cytotoxicity against HCT116, HT29 and SW480 colon cancer cells. It was found that two compounds (C4 and C5) exhibited strong anti-colon cancer activities. These two compounds were used to study their properties that include MTT activity (with IC50 of C4 as 74.71, 129.0 and 131.4 µg/ml in HCT116, HT29 and SW480 respectively, whereas IC50 of C5 as 128.1, 168.4 and 225.8 µg/ml in HCT116, HT29 and SW480 cells respectively), colony formation activity, wound healing activity, spheroid formation activity, DAPI-PI staining, acridine-orange and ethidium bromide staining, ROS measurement, and rhodamine-123 staining in both HCT116 and HT29 colon cancer cells. Both the compounds showed significant increase in apoptosis as visualized by 4',6-diamidino-2-phenylindol/propidium iodide (DAPI-PI) and acridine orange/ethidium bromide (AO/EtBr) staining. The induction of apoptosis was further confirmed by the expressions of cleaved PARP and caspase 3. ROS generation and its effect on MMP were measured by staining cells with Dichloro-dihydro-fluorescein diacetate (DCFH-DA) and Rhodamine. Expression levels of EMT associated markers like Cyclin D1, Slug, Vimentin, and E-Cadherin were also studied. Both the compounds down regulate protein levels of Slug, Cyclin D1, and Vimentin in a concentration-dependent manner. Eeffect of C4 and C5 compounds on key signaling protein like Wnt3a, Notch1, and Shh were evaluated. Additionally, mRNA levels of these genes were also analyzed. C4 exhibited the best binding affinity when docked with Shh and Wnt3a and Notch1. Similarly, C5 exhibited - 8.8, -8.2 and - 7.6 kcal⋅mol
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.